These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 8833400

  • 1. Vincristine degradation by serum from leukemic patients: role of myeloperoxidase.
    Schlaifer D, Duchayne E, Demur C, Alvinerie P, Muller C, Attal M, Cooper MR, Payen C, Monsarrat B, Myers CE, Pris J, Laurent G.
    Leuk Lymphoma; 1996 Feb; 20(5-6):441-6. PubMed ID: 8833400
    [Abstract] [Full Text] [Related]

  • 2. Degradation of vincristine by myeloperoxidase and hypochlorous acid in children with acute lymphoblastic leukemia.
    Ozgen U, Türköz Y, Stout M, Ozuğurlu F, Pelik F, Bulut Y, Aslan M, Ravindranath Y, Savaşan S.
    Leuk Res; 2003 Dec; 27(12):1109-13. PubMed ID: 12921949
    [Abstract] [Full Text] [Related]

  • 3. Further elucidation of mechanism of resistance to vincristine in myeloid cells: role of hypochlorous acid in degradation of vincristine by myeloperoxidase.
    Ozgen U, Savaşan S, Stout M, Buck S, Ravindranath Y.
    Leukemia; 2000 Jan; 14(1):47-51. PubMed ID: 10637476
    [Abstract] [Full Text] [Related]

  • 4. Potential strategies for circumventing myeloperoxidase-catalyzed degradation of vinca alkaloids.
    Schlaifer D, Cooper MR, Attal M, Rousseau A, Pris J, Laurent G, Myers CE.
    Leukemia; 1994 Apr; 8(4):668-71. PubMed ID: 8152263
    [Abstract] [Full Text] [Related]

  • 5. Antisense inhibition of myeloperoxidase increases the sensitivity of the HL-60 cell line to vincristine.
    Schlaifer D, Meyer K, Muller C, Attal M, Smith MT, Tamaki S, Weimels J, Pris J, Jaffrézou JP, Laurent G.
    Leukemia; 1994 Feb; 8(2):289-91. PubMed ID: 7905941
    [Abstract] [Full Text] [Related]

  • 6. Increased 14-3-3ζ expression in the multidrug-resistant leukemia cell line HL-60/VCR as compared to the parental line mediates cell growth and apoptosis in part through modification of gene expression.
    Liang R, Chen XQ, Bai QX, Wang Z, Zhang T, Yang L, Dong BX, Gao GX, Gu HT, Zhu HF.
    Acta Haematol; 2014 Feb; 132(2):177-86. PubMed ID: 24603438
    [Abstract] [Full Text] [Related]

  • 7. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells.
    Kim YR, Eom JI, Kim SJ, Jeung HK, Cheong JW, Kim JS, Min YH.
    J Pharmacol Exp Ther; 2010 Nov; 335(2):389-400. PubMed ID: 20699435
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia.
    Roberson JR, Onciu M, Pounds S, Rubnitz JE, Pui CH, Razzouk BI.
    Pediatr Blood Cancer; 2008 Mar; 50(3):542-8. PubMed ID: 17763467
    [Abstract] [Full Text] [Related]

  • 9. Myeloperoxidase: an enzyme involved in intrinsic vincristine resistance in human myeloblastic leukemia.
    Schlaifer D, Cooper MR, Attal M, Sartor AO, Trepel JB, Laurent G, Myers CE.
    Blood; 1993 Jan 15; 81(2):482-9. PubMed ID: 8380727
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous occurrence of terminal deoxynucleotidyl transferase and myeloperoxidase in individual leukemia blasts.
    Lanham GR, Bollum FJ, Williams DL, Stass SA.
    Blood; 1984 Jul 15; 64(1):318-20. PubMed ID: 6329379
    [Abstract] [Full Text] [Related]

  • 11. Myeloperoxidase is a key regulator of oxidative stress mediated apoptosis in myeloid leukemic cells.
    Nakazato T, Sagawa M, Yamato K, Xian M, Yamamoto T, Suematsu M, Ikeda Y, Kizaki M.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 1):5436-45. PubMed ID: 17875773
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Myeloperoxidase cytochemical negativity: an unexpected but intrinsic property of blasts of all phases of chronic myeloid leukemia.
    Anand M, Ghara N, Kumar R, Singh S, Sengar M, Panikar N, Raina V, Sharma A.
    Ann Hematol; 2005 Nov 15; 84(12):767-70. PubMed ID: 15990995
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
    Silverman JA, Reynolds L, Deitcher SR.
    J Clin Pharmacol; 2013 Nov 15; 53(11):1139-45. PubMed ID: 23907766
    [Abstract] [Full Text] [Related]

  • 16. The differentiating effect of retinoic acid and vincristine on acute myeloid leukemia.
    Leung MF, Wong KF.
    J Hematother; 1999 Jun 15; 8(3):275-9. PubMed ID: 10417051
    [Abstract] [Full Text] [Related]

  • 17. Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine.
    Baran Y, Gunduz U, Ural AU.
    Exp Oncol; 2006 Jun 15; 28(2):163-5. PubMed ID: 16837911
    [Abstract] [Full Text] [Related]

  • 18. [Transdermal and lymph targeting transfersomes of vincristine].
    Lu Y, Hou SX, Zhang LK, Li Y, He JY, Guo DD.
    Yao Xue Xue Bao; 2007 Oct 15; 42(10):1097-101. PubMed ID: 18229621
    [Abstract] [Full Text] [Related]

  • 19. Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase.
    Kagan VE, Kuzmenko AI, Tyurina YY, Shvedova AA, Matsura T, Yalowich JC.
    Cancer Res; 2001 Nov 01; 61(21):7777-84. PubMed ID: 11691792
    [Abstract] [Full Text] [Related]

  • 20. Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.
    Behan JW, Avramis VI, Yun JP, Louie SG, Mittelman SD.
    Pharmacol Res; 2010 May 01; 61(5):385-90. PubMed ID: 20083201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.